revenues, page-28

An announcement of a deal with POC1 might be the worst thing that could happen to ADO's sp long term.
The reality might finally hit home that it's revenue that counts not deals.
Philips at the moment have no share of the Point of Care market.
They have yet to announce a single test that works, though they are working on at least several.
There is a lot of competition from companies already well established in the POCT market.
Abbott Laboratories, Alere Inc., Roche Diagnostics, Boston Scientific Corp, and Medtronic Inc."
There are new companies such as Trinity and this one www.biosensia.com/rapiplex/

So even if Philips minicare is released , it will have a huge fight to gain decent market share
Anteo might or might not be a crucial component of Philips minicare but it will be only a very small component never the less.(1-3%)
A very small component of a small market share means small revenue.
Pretty much just like all their previous deals.